(firstQuint)A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis.

 SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2).

 This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001).

 The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.

.

 A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis@highlight

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

